Document Detail


Gemfibrozil improves abnormalities of lipid metabolism in patients on continuous ambulatory peritoneal dialysis: the role of postheparin lipases in the metabolism of high-density lipoprotein subfractions.
MedLine Citation:
PMID:  2507877     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Twenty-five CAPD patients were given gemfibrozil in increasing doses for a total of 14 weeks. Parameters of lipid metabolism including serum total cholesterol, LDL cholesterol, HDL cholesterol, HDL2 cholesterol, HDL3 cholesterol triglyceride, apolipoprotein A-1, apolipoprotein B, postheparin lipoprotein lipase, and hepatic lipase activities were measured before the commencement, at every increment in the dose of gemfibrozil and 4 weeks after discontinuation of therapy. Gemfibrozil normalized the deranged parameters of lipid metabolism. Thus, with treatment, serum triglyceride, and total cholesterol, LDL cholesterol and apo B decreased, whereas serum HDL cholesterol, HDL2, and HDL3 (predominantly the latter subfraction), hepatic lipoprotein lipase activities increased. Apo A-1 did not change significantly. Even in normotriglyceridemic patients serum HDL cholesterol increased. The side effects consisted of muscle aches and a significant rise in serum CPK. Gemfibrozil produced a significant decrease in gamma-GT activities. A possible mechanism for the interconversion between HDL2 and HDL3 that resulted in a preferential increase in the latter was discussed. It was concluded that gemfibrozil, in a dose not exceeding 300 mg twice a day favorably improved the risk factor for ischemic heart disease in CAPD patients.
Authors:
M K Chan
Related Documents :
7025257 - The effects of labetalol and oxprenolol on blood lipids.
12643187 - The effect of dietary intervention on serum lipid levels in type 2 diabetes mellitus.
8574257 - Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and de...
18454257 - Natural honey and cardiovascular risk factors; effects on blood glucose, cholesterol, t...
6168217 - Comparison of the content of chlorinated pesticide residues in human semen, testicles a...
7484937 - Sugar substitutes: their energy values, bulk characteristics, and potential health bene...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Metabolism: clinical and experimental     Volume:  38     ISSN:  0026-0495     ISO Abbreviation:  Metab. Clin. Exp.     Publication Date:  1989 Oct 
Date Detail:
Created Date:  1989-11-14     Completed Date:  1989-11-14     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0375267     Medline TA:  Metabolism     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  939-45     Citation Subset:  IM    
Affiliation:
Department of Medicine, University of Hong Kong, Queen Mary Hospital.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Apolipoprotein A-I
Apolipoproteins A / metabolism
Apolipoproteins B / metabolism
Cholesterol / metabolism
Cholesterol, HDL / metabolism
Cholesterol, LDL / metabolism
Drug Evaluation
Female
Gemfibrozil / administration & dosage,  therapeutic use*
Humans
Hyperlipidemias / prevention & control*
Lipid Metabolism*
Lipoprotein Lipase / metabolism*
Lipoproteins, HDL / metabolism*
Liver / enzymology,  metabolism
Male
Middle Aged
Peritoneal Dialysis, Continuous Ambulatory* / adverse effects
Time Factors
Triglycerides / metabolism
Chemical
Reg. No./Substance:
0/Apolipoprotein A-I; 0/Apolipoproteins A; 0/Apolipoproteins B; 0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Lipoproteins, HDL; 0/Triglycerides; 25812-30-0/Gemfibrozil; 57-88-5/Cholesterol; EC 3.1.1.34/Lipoprotein Lipase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Long-term follow-up after early protein-calorie malnutrition in young rats: sex difference in glucos...
Next Document:  N-acetyl-L-tyrosine and N-acetyl-L-cysteine as tyrosine and cysteine precursors during intravenous i...